Vice President, Market Access, EMEA

This leader will shape and lead value and access submission and negotiation planning, including optimal country launch sequence and ensure sustainable access in key European markets. Reporting to the SVP, European GM, this role will be a core member of the Europe Region leadership team, working cross-functionally to influence long-term growth and patient impact, to build a global multi-billion company serving patients suffering from rare neuro-muscular diseases, starting with SMA as an indication. The EMEA Value & Access Lead is a pivotal member of the Global Value & Access Team leading the market access launch of apitegromab for spinal muscular atrophy (SMA) starting with Germany and setting the sequence of launches in the other EMEA markets. Accountable for securing pricing and reimbursement for appropriate patients in EMEA, starting in Germany, and setting appropriate launch sequence after Germany. This is an opportunity for an entrepreneurial individual to help shape the trajectory of our first Commercial launch. A successful candidate will be based in Zug, Switzerland, fluent in business German and English, and have a track record of launching and negotiating access for rare disease drugs in Europe.